Kromek Group plc (LSE:KMK) has reported a sharp increase in revenue for the first half of 2026, expecting at least £14.5 million compared to £3.7 million in the same period last year. This strong performance has been driven primarily by the company’s CBRN Detection division and a significant contribution from its agreement with Siemens Healthineers.
Kromek anticipates posting a profit before tax and positive adjusted EBITDA for the period, marking a turnaround from the previous year’s losses. These results bolster confidence in the company’s ability to meet full-year market expectations and highlight the growing commercial strength of its product portfolio.
The company’s outlook remains positive, supported by strong revenue growth and improving profitability. Technical indicators suggest bullish momentum, though caution is warranted as the RSI approaches overbought territory. Valuation metrics indicate fair pricing, with the P/E ratio reflecting a reasonable market position.
More about Kromek Group plc
Kromek Group plc is a UK-based developer of advanced radiation detection and bio-detection technologies, specializing in imaging and CBRN detection. Headquartered in County Durham with operations in the UK and US, the company supplies detector components for medical, security, and industrial markets and provides nuclear radiation detection solutions for global homeland defense. It is also advancing biosecurity technologies for the detection of airborne pathogens.
Leave a Reply